BioLife Solutions, Inc. (BLFS) – What Are Analysts Saying About This Stock?

BioLife Solutions, Inc. (NASDAQ:BLFS) has been given an average rating of “Hold” by the eleven brokerages that are currently covering the company, MarketBeat Ratings reports. Ten analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $31.38.

Several equities analysts recently weighed in on BLFS shares. Wall Street Zen cut BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Saturday, July 25th. HC Wainwright lowered BioLife Solutions from a “buy” rating to a “neutral” rating and lowered their target price for the company from $32.00 to $31.00 in a report on Thursday, July 23rd. Lake Street Capital downgraded BioLife Solutions from a “buy” rating to a “hold” rating and dropped their price target for the stock from $33.00 to $31.00 in a research report on Wednesday, July 22nd. Weiss Ratings upgraded BioLife Solutions from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday, September 22nd. Finally, Zacks Research cut BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 21st.

BioLife Solutions Price Performance

BLFS opened at $38.61 on Monday. BioLife Solutions has a fifty-two week low of $17.86 and a fifty-two week high of $39.76. The business has a 50-day moving average of $36.36 and a 200-day moving average of $28.71. The company has a market capitalization of $1.89 billion, a PE ratio of 33.28 and a beta of 1.82.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.88. BioLife Solutions had a return on equity of 2.70% and a net margin of 53.29%. The business had revenue of $28.47 million during the quarter, compared to analyst estimates of $27.80 million. On average, equities research analysts expect that BioLife Solutions will post 0.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioLife Solutions

Large investors have recently bought and sold shares of the stock. GAMMA Investing LLC raised its position in BioLife Solutions by 7.2% in the 3rd quarter. GAMMA Investing LLC now owns 9,647 shares of the medical equipment provider’s stock valued at $375,000 after purchasing an additional 651 shares during the last quarter. Tidal Investments LLC acquired a new position in shares of BioLife Solutions during the second quarter valued at $819,000. WINTON GROUP Ltd bought a new position in BioLife Solutions in the second quarter valued at about $201,000. Engineers Gate Manager LP bought a new position in BioLife Solutions in the second quarter valued at about $424,000. Finally, Squarepoint Ops LLC acquired a new stake in BioLife Solutions in the second quarter worth about $3,754,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc is a life sciences technology company that develops and supplies products used to preserve, store, process and transport cells and tissues. Its solutions support the development and commercialization of cell and gene therapies, as well as other biological materials that require controlled temperature and handling conditions.

The company’s product portfolio includes biopreservation media such as CryoStor and HypoThermosol, cryogenic storage bags and containers, controlled-rate freezing systems, automated thawing equipment and related laboratory tools.